Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618000246280
Ethics application status
Approved
Date submitted
5/12/2017
Date registered
15/02/2018
Date last updated
15/02/2018
Type of registration
Retrospectively registered

Titles & IDs
Public title
Performance of a new preloaded fiducial needle for guided radiation therapy of upper gastrointestinal cancers
Scientific title
Performance of a new preloaded fiducial needle for guided radiation therapy of upper gastrointestinal cancers
Secondary ID [1] 293537 0
none
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastrointestinal Cancers 305735 0
Condition category
Condition code
Cancer 304952 304952 0 0
Oesophageal (gullet)
Cancer 304954 304954 0 0
Pancreatic
Cancer 304955 304955 0 0
Liver
Cancer 304956 304956 0 0
Biliary tree (gall bladder and bile duct)

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Data on patients who underwent EUS-guided fiducial placement for stereotactic body radiotherapy (SBRT) or brachytherapy for gastrointestinal (GI) malignancies were retrospectively and prospectively recruited over 2 years. Visicoil Linear Fiducial Markers (Dosimetry, Schwarzenbruck, Germany) and fiducial bars from the EchoTip Fiducial Needle (Cook Medical, Indiana, United States) were used. Either conventional Viscoils (10mm gold-coils), or the new 22G fiducial needle preloaded with 4x5mm long gold bars were used and the choice was at the discretion of the endoscopists.
For the preloaded system, four 5mm gold bars are part of a 22G needle and are preloaded at the tip of the needle. This allows the fiducials to be deployed to target lesions consecutively in a short amount of time, and avoid the need of withdrawing the needle to load the subsequent fiducials. There are small spaces between the preloaded fiducials, assisting the endoscopist to know when the fiducial is deployed.
In all cases, the procedure was performed with the GF-UCT180 linear echoendoscope (Olympus, Center Valley, PA, USA) and fluoroscopy was used when available. All insertions were done by a single, highly experienced endosonographer with the patients under sedation with Propofol by a specialist anaesthetist. All patients received prophylactic intra-venous anti-biotics during the procedure (Ceftriaxone 1gm or Clindamycin 600mg). The number of fiducials placed was at the discretion of the endosonographer with the aim being 1-4. All patients were monitored for a minimum of 2 hours post-procedure for any early complications and were also advised to contact the centre or doctor for any delayed symptoms suggestive of complications. Patients were also assessed in clinic for any complications 30 days post-procedure.
Intervention code [1] 299771 0
Diagnosis / Prognosis
Comparator / control treatment
The performance of the conventional coil fiducial (Visicoil) will be the control treatment, and will be compared the new EUS preloaded fiducial needle (Cook Medical), for stereotactic body radiotherapy and brachytherapy.

The method for loading and deploying the Visicoil Fiducials required using a 22G or 19G EchoTip needle, which was chosen at the discretion of the endoscopist. This approach requires individual loading of a single fiducial to the tip of a FNA needle prior to each single deployment.
The number of fiducials placed was at the discretion of the endosonographer with the aim being 1-4. These were placed by trained endoscopist using echoendoscope and fluroscopy under anaethesia.
All patients received prophylactic intra-venous anti-biotics during the procedure (Ceftriaxone 1gm or Clindamycin 600mg).

Patients were monitored for a minimum of 2 hours post-procedure for any early complications and assessed 30 days post-operatively.
Control group
Active

Outcomes
Primary outcome [1] 304136 0
To compare the performance of a new EUS preloaded fiducial needle (Cook Medical) against the conventional coil fiducial (Visicoil) for SBRT and brachytherapy.

This is defined as technical success; the ability to place 1 or more fiducials in the desired location (with endoscopic ultrasound assessment immediately after deployment). The number of fiducials placed was at the discretion of the endosonographer, with the aim being 1-4.
Timepoint [1] 304136 0
This outcome is assessed within 2 days of the procedure.
Secondary outcome [1] 341068 0
To compare the number of fiducials placed. The number of fiducials placed was at the discretion of the endosonographer with the aim being 1-4.
Timepoint [1] 341068 0
This outcome is assessed within 2 days of the procedure.
Secondary outcome [2] 341070 0
Procedural complications. This includes gastrointestinal perforation, bleeding, post-procedure pancreatitis, infections or seed migration requiring re-insertion.
Timepoint [2] 341070 0
All patients were monitored for a minimum of 2 hours post-procedure for any early complications and were also advised to contact the centre or doctor for any delayed symptoms suggestive of complications. Patients were also assessed in clinic for any complications 30 days post-procedure.
Secondary outcome [3] 341072 0
To compare the fiducial insertion time. This is defined as the total time taken to load the fiducials, insert the needle into the lesion and to deploy the fiducials..
Timepoint [3] 341072 0
This outcome is assessed at the time of the fiducial insertion.
Secondary outcome [4] 341074 0
To compare fiducial visability. This is assessed by visual analogue scale from 0 to 2, where a score of 0 is not visible, 1 is barely visible, and 2 is clearly visible. The score was assessed from images of CT scans as well as fluoroscopic images.
Timepoint [4] 341074 0
This outcome is assessed within 2 days of the procedure.

Eligibility
Key inclusion criteria
1. Only patients with gastrointestinal malignancy, confirmed by a cytopathologist.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Pregnancy.

2. Those who cannot provide informed consent.

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
5/12/2017
Date of last participant enrolment
Anticipated
Actual
29/12/2017
Date of last data collection
Anticipated
Actual
5/01/2018
Sample size
Target
55
Accrual to date
Final
55
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 9493 0
The Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 18233 0
5000 - Adelaide

Funding & Sponsors
Funding source category [1] 298151 0
Hospital
Name [1] 298151 0
Royal Adelaide Hospital
Country [1] 298151 0
Australia
Primary sponsor type
Hospital
Name
Royal Adelaide Hospital
Address
Department of Gastroenterology and Hepatology,
Port Road, Adelaide,
SA 5000
Country
Australia
Secondary sponsor category [1] 297238 0
None
Name [1] 297238 0
Address [1] 297238 0
Country [1] 297238 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 299165 0
Royal Adelaide Hospital Human Research Ethics Committee
Ethics committee address [1] 299165 0
Ethics committee country [1] 299165 0
Australia
Date submitted for ethics approval [1] 299165 0
Approval date [1] 299165 0
04/12/2017
Ethics approval number [1] 299165 0
HREC/17/RAH/549

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 79518 0
Dr Vinh-An Phan
Address 79518 0
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Port Road, Adelaide, South Australia, Australia 5000.
Country 79518 0
Australia
Phone 79518 0
+61870742189
Fax 79518 0
Email 79518 0
[email protected]
Contact person for public queries
Name 79519 0
Romina Safaeian
Address 79519 0
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Port Road, Adelaide, South Australia, Australia 5000.
Country 79519 0
Australia
Phone 79519 0
+61870742189
Fax 79519 0
Email 79519 0
[email protected]
Contact person for scientific queries
Name 79520 0
Romina Safaeian
Address 79520 0
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Port Road, Adelaide, South Australia, Australia 5000.
Country 79520 0
Australia
Phone 79520 0
+61870742189
Fax 79520 0
Email 79520 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.